Apr 28, 2022 / 03:30PM GMT
Mayank Mamtani - B. Riley Securities, Inc. - Analyst
Good morning. Thank you all for joining us for our next fireside chat with AC Immune CEO, Professor Andrea Pfeifer. Thank you, Andrea, for joining us. I know you have a lot going on, and you are in a completely different time zone, so all the more appreciate it.
And maybe we can get started with a high-level overview of your pipeline focused on neurodegenerative diseases coming across therapeutics and diagnostics. And then obviously, we have a ton to talk about as we deep dive into your programs.
Andrea Pfeifer - AC Immune SA - Co-Founder, CEO & Director
Yes. So I think, starting off, it would be very important to basically talk about the upcoming milestones. So as you know, we have pipeline targeting Tau, Abeta, alpha-synuclein in late-stage disease. And we have a preclinical pipeline targeting inflammasome, TDP-43.
So on the late-stage pipeline, we are really looking forward to the readout of the API study, evaluating consumer -- the anti-Abeta antibody in a genetic population in
AC Immune SA at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers